We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 872

News and cases from China: August - September 2015
  • Rouse
  • China
  • October 29 2015

Recently, the National Copyright Administration issued Implementing Measures for the Copyright Administrative Penalties (Revision Draft for Comment

  • Beijing Sanyou Intellectual Property Agency Ltd
  • China
  • September 11 2015


China’s national antitrust authority fights administrative monopoly in Provincial Government drug procurement programs
  • Sidley Austin LLP
  • China
  • September 7 2015

On August 17, 2015, one of China's antitrust enforcement authorities, the National Development & Reform Commission (NDRC), issued a letter to the

Antitrust in China's pharma sector Bengbu action following big-bang reform
  • Hogan Lovells
  • China
  • September 1 2015

On 26 August 2015, the National Development and Reform Commission ("NDRC") made public its first antitrust enforcement decision in the pharmaceutical

Experimental use exemption of patent infringement ̶ a brief comparison of China and the United States
  • Peksung Intellectual Property Ltd
  • China, USA
  • February 3 2015

Generally, the purpose of a patent is to award the patentee a limited market monopoly for disclosing his invention to the public. Experimental use of

Global intellectual property newsletter - issue 0115
  • Clifford Chance LLP
  • China, European Union, Germany, Poland, Spain, United Kingdom, USA
  • January 21 2015

Establishment of the Unified European Patent Litigation System has been subject to many efforts of European leaders and legislators for more than four

GSK bribery conviction signals increased risks in China
  • Fenwick & West LLP
  • China, USA
  • October 21 2014

On September 19, 2014, a Chinese court found pharmaceutical giant GlaxoSmithKline PLC (GSK) guilty of bribing doctors and hospitals in order to

Privacy & cybersecurity update, issue 3 - October, 2014
  • Jones Day
  • Australia, Brazil, Canada, Russia, Taiwan, USA, Ireland, Italy, Japan, Mexico, Netherlands, New Zealand, Chile, China, European Union, France, Germany, Hong Kong
  • October 15 2014

On August 1, the Federal Trade Commission ("FTC") issued a report on mobile shopping applications. In it, the FTC found that such apps often fail to

GlaxoSmithKline and five executives convicted of bribery in China
  • Fenwick & West LLP
  • China, USA
  • September 24 2014

On Friday, September 19, 2014, a Chinese court found pharmaceutical giant GlaxoSmithKline guilty of bribing doctors and hospitals in order to

GSK China fined a record $492 million for bribery in China
  • Herbert Smith Freehills LLP
  • China
  • September 22 2014

In a landmark case, a Chinese court has fined GlaxoSmithKline's China subsidiary (GSK China) US$ 492 million dollars for bribing doctors and